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Abstract
Purpose Pre-clinical animal studies precede the majority of clinical trials. While the clinical sepsis definitions and recom-
mended treatments are regularly updated, a systematic review of pre-clinical models of sepsis has not been done and clear 
modeling guidelines are lacking. To address this deficit, a Wiggers-Bernard Conference on pre-clinical sepsis modeling was 
held in Vienna in May, 2017. The conference goal was to identify limitations of pre-clinical sepsis models and to propose 
a set of guidelines, defined as the “Minimum Quality Threshold in Pre-Clinical Sepsis Studies” (MQTiPSS), to enhance 
translational value of these models.
Methods 31 experts from 13 countries participated and were divided into 6 thematic Working Groups (WG): (1) Study 
Design, (2) Humane modeling, (3) Infection types, (4) Organ failure/dysfunction, (5) Fluid resuscitation and (6) Antimi-
crobial therapy endpoints. As basis for the MQTiPSS discussions, the participants conducted a literature review of the 260 
most highly cited scientific articles on sepsis models (2002–2013).
Results Overall, the participants reached consensus on 29 points; 20 at “recommendation” (R) and 9 at “consideration” (C) 
strength. This Executive Summary provides a synopsis of the MQTiPSS consensus (Tables 1, 2 and 3).
Conclusions We believe that these recommendations and considerations will serve to bring a level of standardization to 
pre-clinical models of sepsis and ultimately improve translation of pre-clinical findings. These guideline points are proposed 
as “best practices” that should be implemented for animal sepsis models. In order to encourage its wide dissemination, this 
article is freely accessible in Shock, Infection and Intensive Care Medicine Experimental.
Keywords Guidelines · Experiment · Study design · Humane modeling · Infection types · Organ dysfunction · Fluid 
resuscitation · Antimicrobial therapy
“This modeling thing, it’s pretty easy, but actually it’s 
also really tough.” Cara Delevingne
The necessity
With the ultimate goal to reduce mortality/morbidity in 
patients, animal modeling of diseases has been limited by 
poor translation [1, 2]. This is often fueled by the low fidel-
ity of available model systems [3, 4], their inappropriate 
study designs [2] and selective use of animal data [5, 6]. 
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Table 1  Combined Recommendations and Considerations from the Working Group (WG) 1 and 2
R: Recommendation strength; C: consideration strength
Study Design
(WG-1)
1. Survival follow-up should reasonably reflect the clinical time course of the sepsis model R
2. Therapeutic interventions should be initiated after the septic insult replicating clinical care
3. We recommend that the treatment be randomized and blinded when feasible
4. Provide as much information as possible (e.g. ARRIVE guidelines) on the model and methodology, to 
enable replication.
a. Consider replication of the findings in models that include co-morbidity and/or other biological variables 
(i.e., age, gender, diabetes, cancer, immuno-suppression, genetic background and others).
C
b. In addition to rodents (mice and rats), consider modeling sepsis also in other (mammal) species.
c. Consider need for source control
Humane Modeling
(WG-2)
5. The development and validation of standardized criteria to monitor the well-being of septic animals is 
recommended
R
6. The development and validation of standardized criteria for euthanasia of septic animals is recommended 
(exceptions possible)
7. Analgesics recommended for surgical sepsis consistent with ethical considerations
d. Consider analgesics for nonsurgical sepsis C
Table 2  Combined Recommendations and Considerations from the Working Group (WG) 3 and 4
R: Recommendation strength; C: consideration strength
Infection Types
(WG-3)
8. We recommend that challenge with LPS is not an appropriate model for replicating human sepsis R
9. We recommend that microorganisms used in animal models preferentially replicate those commonly found 
in human sepsis
e. Consider modeling sepsis syndromes that are initiated at sites other than the peritoneal cavity (e.g. lung, 
urinary tract, brain)
C
Organ Failure/ Dysfunction
(WG-4)
10. Organ/system dysfunction is defined as life threatening deviation from normal for that organ/system 
based on objective evidence
R
11. Not all activities in an individual organ/system need to be abnormal for organ dysfunction to be present
12. To define objective evidence of the severity of organ/system dysfunction, a scoring system should be 
developed, validated and used, or use an existing scoring system.
13. Not all experiments must measure all parameters of organ dysfunction but animal models should be
fully exploited
f. Avoid hypoglycemia C
Table 3  Combined Recommendations and Considerations from the Working Group (WG) 5 and 6
R: Recommendation strength; C: consideration strength
Fluid Resuscitation
(WG-5)
14. Fluid resuscitation is essential unless part of the study R
15. Administer fluid resuscitation based on the specific requirements of the model
16.  Consider the specific sepsis model for the timing of the start and continuation for fluid resuscita-
tion
17.  Resuscitation is recommended by the application of iso-osmolar crystalloid solutions
g. Consider using pre-defined endpoints for fluid resuscitation as deemed necessary C
h. Avoid fluid overload
Anti-microbial Therapy
 (WG-6)
18. Antimicrobials are recommended for pre-clinical studies assessing potential human therapeutics R
19. Antimicrobials should be chosen based on the model and likely/known pathogen
20. Administration of antimicrobials should mimic clinical practice
i. Antimicrobials should be initiated after sepsis is established C
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When compared to other inflammatory states (e.g. arthritis, 
atherosclerosis), the complexity of sepsis has hampered the 
development of high-fidelity models. However, this chal-
lenge can be aptly embraced by building on recent advances 
in the understanding of sepsis pathophysiology and avoid-
ing past errors. Any promising sepsis model must be (a) 
specifically tailored to the posited hypothesis, (b) “reverse 
translated” to its clinical counterpart [7, 8] and (c) adjusted 
as new pathophysiological evidence emerges. This is echoed 
by the US Food and Drug Administration (FDA) in their 
2010 Guidance for Industry and FDA Staff: “FDA believes 
that the animal…(model)…should provide a test system that 
offers a best attempt at simulating the clinical setting”. (Gen-
eral Considerations for Animal Studies for Cardiovascular 
Devices; http://www.fda.gov).
Unfortunately, while the clinical definition of sepsis is 
currently in its third iteration [9] and the Surviving Sepsis 
Campaign (SSC) Guidelines for patient management have 
been updated three times [10], pre-clinical sepsis research 
has not been subjected to any organized attempt at introduc-
ing best practices, management guidelines and standardiza-
tion [11]. This creates a large quality gap and confusion with 
conflicting data reflecting huge variations in, for example, 
insult severity, fluid resuscitation and study duration. Effec-
tive animal modeling and reporting guidelines have recently 
been proposed for other specific diseases such as pulmonary 
fibrosis [12], stroke [13, 14], heart failure [15] and malaria 
[16] making the void in the field of pre-clinical sepsis even 
more apparent. It is essential that animal models of sep-
sis continue to evolve. Lack of sufficient standardization of 
preclinical models will continue to limit the utility of sepsis 
animal research as a useful platform for advancing clinical 
outcomes and care in sepsis [17, 18] and will reduce the 
opportunities to identify and test new therapies.
The action
To address this perceived deficit, the Ludwig Boltzmann 
Institute of Experimental and Clinical Traumatology in the 
AUVA Research Center organized in May 2017 in Vienna 
a Wiggers-Bernard Conference on “Pre-clinical Modeling 
in Sepsis: Exchanging Opinions and Forming Recommen-
dations”. The key goal was to create publishable mate-
rial that characterizes elements that should be included 
in pre-clinical sepsis studies and defined by the so called 
“Minimum Quality Threshold in Pre-Clinical Sepsis Stud-
ies” (MQTiPSS) descriptor. The Wiggers-Bernard Confer-
ence participants identified and addressed several broad, 
critically-important concepts in animal sepsis modeling. 
A total of 31 experts from 13 countries participated in the 
initiative (including five members of the Sepsis-3 defini-
tions task force) and were divided into 6 thematic Working 
Groups: (1) study design, (2) humane endpoints, (3) infec-
tion types, (4) organ failure/dysfunction, (5) critical fluid 
resuscitation and (6) antimicrobial therapy.
The initiative consisted of three phases: (a) prepara-
tory (prior to the meeting; approximately 3 months), dur-
ing which participants performed a systematic review 
of the 260 top cited (over 29,000 citations in aggregate) 
2003–2012 pre-clinical publications (using ISI Web of 
Knowledge database; query: “sepsis model”; 374 individ-
ual experiments analyzed) and identified the key modeling 
topics to be discussed, (b) discussion during which the 
participants spent 2 days at the Wiggers-Bernard Confer-
ence examining pre-clinical sepsis models and ultimately 
voted to reach consensus on the proposed points (either at 
the “recommendation” or “consideration” strength), and 
(c) post-meeting refinement of the accepted points and 
finalization of the arguments to be included in the final 
publications (using a modified Delphi method; approxi-
mately 3 months). Following the format used by the Sep-
sis-3 task force [8], at least 2/3 (over 65%) of the votes 
were required for approval of a proposed point.
The proposed outcome
First, a definition for an animal model of sepsis was formu-
lated and (unanimously) approved: “An experimental ani-
mal (mammal) model of sepsis should be defined as life-
threatening organ dysfunction caused by a dysregulated 
host response to an infection.” Second, Wiggers-Bernard 
Conference participants reached consensus on 29 points; 
20 at “recommendation” strength and 9 at “consideration” 
strength (listed in Tables 1, 2 and 3). All consensus points 
were reached either unanimously or with no more than 2 
abstentions per point (point 8). The “recommendation” 
strength indicates virtually unanimous agreement among 
the 31 participants, regarding both the content and the 
need for rapid implementation. Issues that require addi-
tional discussion before final recommendations could be 
made were classified as considerations.
The current executive summary briefly describes the 
Wiggers–Bernard Conference initiative and presents the 
compiled consensus points. The details of the recommen-
dations/considerations are published in three separate 
papers [19–21] subsequently appearing in the 2019 Janu-
ary issue of the Shock journal. The Tables 1, 2 and 3 sum-
marize the main MQTiPSS consensus points published in 
those articles: Part I—Table 1 [19], Part II – Table 2 [20] 
and Part III—Table 3 [21]. Each publication is built on two 
(related) Working Group themes and includes a narrative 
clarifying caveats and intricacies related to the accepted 
consensus points.
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The future
The presented consensus has not received formal endorse-
ment from professional bodies. Writing an initial consensus 
was a strategic decision given that an expert opinion report 
has a shorter publication turnaround and our intention was to 
rapidly introduce the MQTiPSS concept. The Wiggers–Ber-
nard Conference was conceived not as a one-time event but 
rather as an initial “call-to-arms”; an invitation to interested 
parties to provide further refinement and expansion of the 
proposed points. The on-going expansion initiatives include 
formation of a Task Force (under the auspices of the Shock 
Society; June 2017) for creation of robust, defined param-
eters to score sepsis models for clinical relevance. Another 
iteration of the Wiggers-Bernard Conference on animal 
sepsis models is planned for October 2019 at the joint con-
ference of the European Shock Society and International 
Federation of Shock Societies in Crete, Greece.
In summary, we believe that the proposed guidelines rep-
resent the first concrete steps toward creation of a realistic 
framework for standardization of animal models of sepsis 
(i.e. MQTiPSS). Such a framework, once widely employed, 
will improve the quality of pre-clinical investigation and arm 
clinicians with better tools for combating sepsis in patients.
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